Interestingly, when p38MAPK activation was blocked by the p38MAPK inhibitor SB203580, pyrimethamine-induced activation of p53 was partly abrogated in CRC cells (Fig. 3c). The gene discussed is TP53; the disease is colorectal carcinoma.